BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,505 | +48.4% | 212,698 | +47.6% | 0.02% | +66.7% |
| Q2 2023 | $1,014 | +95.8% | 144,062 | +131.5% | 0.01% | +50.0% |
| Q1 2023 | $518 | -99.8% | 62,223 | +161.4% | 0.01% | +100.0% |
| Q3 2022 | $299,000 | -83.5% | 23,803 | -81.1% | 0.00% | -72.7% |
| Q3 2021 | $1,812,000 | -3.3% | 126,125 | +6.4% | 0.01% | -35.3% |
| Q2 2021 | $1,874,000 | +362.7% | 118,550 | +197.6% | 0.02% | +325.0% |
| Q1 2021 | $405,000 | -82.0% | 39,830 | -86.8% | 0.00% | -91.1% |
| Q4 2020 | $2,247,000 | +916.7% | 301,682 | +289.6% | 0.04% | +350.0% |
| Q3 2019 | $221,000 | +35.6% | 77,424 | +605.6% | 0.01% | -87.0% |
| Q2 2015 | $163,000 | – | 10,973 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |